DRAP Hardship Drug Pricing Delay Squeezes Margins: SEARL, AGP in Focus

What the hardship pricing delay changed

Pakistan's drug regulator, DRAP, runs a separate fast-track category for "hardship cases": essential, low-price medicines whose production has become loss-making because their retail price has stayed frozen for years while raw material, packaging, and energy costs kept rising. Manufacturers apply for a price increase under this category specifically to keep supplying drugs that would otherwise be dropped. According to this report, a backlog in approving these hardship cases is now starting to show up as real shortages of some life-saving medicines on pharmacy shelves.

Why it matters for pharma stocks

Pricing approval speed is one of the few levers a listed pharma company has over its own margins in Pakistan, since retail drug prices are capped and can only move with DRAP's sign-off. When hardship-case approvals stall, companies that still manufacture those essential lines are stuck selling below cost, which either eats into overall margins or pushes them to quietly stop production of the affected products. Neither outcome is good for revenue from that segment, though the damage stays contained to specific product lines rather than a company's whole portfolio.

Which stocks, and why

The Searle Company is a useful example because its revenue is explicitly tied to how quickly DRAP approves price increases on its branded portfolio, and it carries several older, lower-priced products that would typically fall into the hardship category. A prolonged approval backlog is a mild drag on margins for that part of its business.

AGP Limited is in a similar position. It is a branded generics maker where steady demand and timely pricing approvals are both needed to keep older, low-margin products viable. If the backlog persists, it adds cost pressure to that segment without changing anything else about the company's underlying operations.

The effect for both is best read as a background margin headwind on specific legacy product lines, not a hit to the companies as a whole. Larger, more diversified names in the sector are less exposed since hardship-case products are typically a small slice of a broad portfolio.

What to watch

The clearest signal will be whether DRAP clears the hardship-case backlog and how many approvals it grants in the coming weeks. A faster clearance would ease the pressure on legacy product margins. If the backlog keeps growing and more essential drugs disappear from pharmacies, expect louder complaints from manufacturers and possibly a policy response, since sustained shortages of life-saving medicines tend to draw government attention faster than routine pricing disputes.